We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Sucampo Pharmaceuticals, Inc. (delisted) | NASDAQ:SCMP | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 18.00 | 18.00 | 18.00 | 0 | 01:00:00 |
(1) 3,126,299 shares of Class A Common Stock, are held by ING Bank N.V., a direct wholly-owned subsidiary of ING Groep N.V., and ING Groep N.V. may be deemed the beneficial owner of the 3,126,299 shares of Class A Common Stock.
(2) Based on 46,636,924 shares of Class A Common Stock issued and outstanding as of October 26, 2017, as reported by the issuer in its Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission on November 1, 2017.
|
Item 1(a).
|
Name of Issuer:
|
|
Sucampo Pharmaceuticals, Inc.
|
||
Item 1(b).
|
Address of Issuer’s Principal Executive Offices:
|
|
805 King Farm Boulevard, Suite 550
Rockville, MD 20850
|
||
Item 2(a).
|
Name of Person Filing:
|
|
ING Groep N.V.
ING Bank N.V.
|
||
Item 2(b).
|
Address of Principal Business Office or, if none, Residence:
|
|
ING Groep N.V.
Bijlmerplein 888
1102 MG
Amsterdam-Zuidoost
Postbus 1800
1000 BV Amsterdam
The Netherlands
ING Bank N.V.
Bijlmerplein 888
1102 MG
Amsterdam-Zuidoost
Postbus 1800
1000 BV Amsterdam
The Netherlands
|
||
Item 2(c).
|
Citizenship:
|
|
ING Groep N.V. – The Netherlands
ING Bank N.V. – The Netherlands
|
||
Item 2(d).
|
Title of Class of Securities:
|
|
Class A Common Stock
|
||
Item 2(e).
|
CUSIP Number:
|
|
864909106
|
||
Item 3.
|
If This Statement is Filed Pursuant to Rule 13d-1(b), 13d-2(b) or (c), Check Whether the Person Filing is a:
|
|
(a)
☐
Broker or dealer registered under Section 15 of the Exchange Act.
(b)
☐
Bank as defined in Section 3(a)(6) of the Exchange Act.
(c)
☐
Insurance company as defined in Section 3(a)(19) of the Exchange Act.
(d)
☐
Investment company as defined under Section 8 of the Investment Company Act.
(e)
☐
An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).
(f)
☐
An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).
(g)
☐
A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G).
(h)
☐
A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
(i)
☐
A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act.
(j)
☐
Group, in accordance with §240.13d-1(b)(1)(ii)(J).
Not Applicable
|
Item 4.
|
Ownership:
|
||
(a)
|
ING Groep N.V. may be deemed to be the beneficial owner of 3,126,299 shares of Class A Common Stock, held by ING Bank N.V., a direct wholly-owned subsidiary. ING Bank N.V. may be deemed the beneficial owner of 3,126,299 shares of Class A Common Stock.
|
||
(b)
|
ING Groep N.V. and ING Bank N.V., a direct wholly-owned subsidiary of ING Groep N.V., may be deemed to be the beneficial owner of 6.70% of Class A Common Stock based on 46,636,924 shares of Class A Common Stock issued and outstanding as of October 26, 2017, as reported by the issuer in its Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission on November 1, 2017.
|
||
(c)
|
Each of ING Groep N.V. and ING Bank N.V. have the shared power to vote and direct the disposition of the 3,126,299 shares of Class A Common Stock, held by ING Bank N.V.
|
||
Item 5.
|
Ownership of Five Percent or Less of a Class:
|
||
Not Applicable.
|
|||
Item 6.
|
Ownership of More than Five Percent on Behalf of Another Person.
|
||
Not Applicable.
|
|||
Item 7.
|
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.
|
||
Not Applicable.
|
|||
Item 8.
|
Identification and Classification of Members of the Group.
|
||
Not Applicable.
|
|||
Item 9.
|
Notice of Dissolution of Group.
|
||
Not Applicable.
|
|||
Item 10.
|
Certification.
|
||
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
|
ING GROEP N.V.
|
||
By:
|
/s/ Fred Severin
|
|
Fred Severin
|
||
Compliance Officer
|
||
By:
|
/s/ M.A. van der Ploeg
|
|
M.A. van der Ploeg
|
||
Head of Data and CoEA
|
||
ING BANK N.V.
|
||
By:
|
/s/ Fred Severin
|
|
Fred Severin
|
||
Compliance Officer
|
||
By:
|
/s/ M.A. van der Ploeg
|
|
M.A. van der Ploeg
|
||
Head of Data and CoEA
|
ING GROEP N.V.
|
||
By:
|
/s/ Fred Severin | |
Fred Severin
|
||
Compliance Officer
|
||
By:
|
/s/ M.A. van der Ploeg | |
M.A. van der Ploeg
|
||
Head of Data and CoEA
|
||
ING BANK N.V.
|
||
By:
|
/s/ Fred Severin | |
Fred Severin
|
||
Compliance Officer
|
||
By:
|
/s/ M.A. van der Ploeg | |
M.A. van der Ploeg
|
||
Head of Data and CoEA
|
1 Year Sucampo Pharmaceuticals, Inc. (delisted) Chart |
1 Month Sucampo Pharmaceuticals, Inc. (delisted) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions